PREVIOUS
✖
WHO report on Dolutegravir
March 11 , 2024
119 days
297
0
- As per the new report by WHO, resistance to the antiretroviral drug dolutegravir (DTG) is increasing among HIV patients.
- Since 2018, WHO has recommended dolutegravir as the preferred first- and second-line HIV treatment due to its effectiveness, ease of use and minimal side effects.
- In 2022, more than 75% of the 39 million people living with HIV globally were receiving HIV treatment.
- 1.3 million new HIV infections and 630,000 HIV-related deaths are reported in 2022.
Leave a Reply
Your Comment is awaiting moderation.